HDAC inhibitors, in particular had recently already been used in experimental trials for the treatment of various cancers, and consequently the earliest trials of shock and kill for patients on ART were performed with the HDAC inhibitors, valproic acid, vorinostat, and more recently panobinostat and romidepsin [81, 104]. The gene discussed is HDAC9; the disease is cancer.